OpGen (MUN:6500) - Stock Price, News & Analysis

6500 Stock Overview

A precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally.

About the company

6500 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Risk Analysis

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Earnings have declined by 12.8% per year over past 5 years

Does not have a meaningful market cap (€16M)

+ 2 more risks

OpGen, Inc. Competitors

Medigene

XTRA:MDG1

€31.0m

co.don

XTRA:CNW

€6.5m

bioXXmed

XTRA:T5O

€1.0m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Price History & Performance

Summary of all time highs, changes and price drops for OpGen
Historical stock prices
Current Share Price	US$1.75
52 Week High	US$3.55
52 Week Low	US$1.58
Beta	-0.66
11 Month Change	1.01%
3 Month Change	-25.58%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-50.12%

Recent updates

Shareholder Returns

	6500	DE Biotechs	DE Market
7D	10.3%	2.2%	-1.9%
1Y	n/a	-9.8%	12.3%

Return vs Industry: Insufficient data to determine how 6500 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 6500 performed against the German Market.

Price Volatility

Is 6500's price volatile compared to industry and market?
6500 volatility
6500 Average Weekly Movement	10.5%
Biotechs Industry Average Movement	6.4%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.8%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: 6500's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 6500's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	93	John Tan	www.opgen.com

OpGen, Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company’s products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services.

OpGen, Inc. Fundamentals Summary

How do OpGen's earnings and revenue compare to its market cap?
6500 fundamental statistics
Market cap	€15.00m
Earnings (TTM)	-€20.40m
Revenue (TTM)	€1.79m

8.4x

P/S Ratio

-0.7x

P/E Ratio

Is 6500 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6500 income statement (TTM)
Revenue	US$1.96m
Cost of Revenue	US$3.48m
Gross Profit	-US$1.52m
Other Expenses	US$20.87m
Earnings	-US$22.39m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.68
Gross Margin	-77.27%
Net Profit Margin	-1,139.66%
Debt/Equity Ratio	-95.1%

How did 6500 perform over the long term?

See historical performance and comparison

OpGen MUN:6500 Stock Report